Clinical Trial Update: A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pyrotinib plus capecitabine for brain metastases in HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: HER2 Positive Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN